The role of biosimilar manufacturers in improving access to insulin globally

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 8, 2017, Pages 578-

  Perrin, Christophe ^a   Ewen, Margaret ^b   Beran, David ^c  

^a Independent Consultant   (France)

^b Vancouver BC   (Netherlands)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; INSULIN DERIVATIVE; INSULIN GLARGINE; ANTIDIABETIC AGENT; BIOSIMILAR AGENT; INSULIN;

DRUG COST; DRUG DEVELOPMENT; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG USE; GOOD MANUFACTURING PRACTICE; HEALTH CARE ACCESS; LETTER; LOW INCOME COUNTRY; MEDICAL EDUCATION; MIDDLE INCOME COUNTRY; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; DRUG INDUSTRY; ECONOMICS; GLOBAL HEALTH; HEALTH CARE DELIVERY; HUMAN;

BIOSIMILAR PHARMACEUTICALS; DRUG INDUSTRY; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 85020494624     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30218-8     Document Type: Letter

References (6)

1. Wirtz, VJ, Hogerzeil, HV, Gray, AL, et al. Essential medicines for universal health coverage. Lancet 389 (2016), 403–476.
2. MSF. Untangling the web of antiretroviral price reduction, 18th edn., 2016, Médecins Sans Frontières, Geneva.
3. Beran, D, Ewen, M, Laing, R, Constraints and challenges in access to insulin: a global perspective. Lancet Diabetes Endocrinol 4 (2016), 275–285.
4. Wirtz, VJ, Insulin market profile, 2016, Health Action International, Amsterdam April, 2016.
5. Owens, DR, Landgraf, W, Schmidt, A, Bretzel, RG, Kuhlmann, MK, The emergence of biosimilar insulin preparations—a cause for concern?. Diabetes Technol Ther 14 (2012), 989–996.
6. GaBI. Biocon receives Japanese approval for insulin glargine biosimilar, April 1, 2016 http://www.gabionline.net/Biosimilars/News/Biocon-receives-Japanese-approval-for-insulin-glargine-biosimilar (accessed April 8, 2017).